Introduction
Gleason grading holds the position as the strongest predictor of survival after initial treatment of prostate cancer. Since the introduction of the Gleason grade patterns and score in 1966, the modifications done to the overall Gleason score (GS) over the years have led to clustering of new prostate cancer diagnoses mainly into GS 6 and 7 [1] [2] [3] . The current consensus is that no GS 2-4 should be assigned in biopsies and even GS 5 is very rare [4] . There is strong evidence that GS 3 + 4 = 7 and 4 + 3 = 7 differ in terms of survival [5, 6] . As a whole, the aforementioned "grade inflation" and sources of confusion for the patients have led to a consensus work-up for a new Grade Group (GG) system recently introduced in the World Health Organization classification for prostate cancer [4, [7] [8] [9] . Histologically, the variable adaptation of the modifications to Gleason grading after the International Society of Urological Pathology (ISUP) 2005 consensus meeting have now been incorporated into a consensus statement with uniform acceptance, and grading is performed with more unified criteria (Fig. 1) . The new grading system allows for easier counseling of patients and has potentially increased predictive value over GS. GGs are formed from the contemporary GS criteria (Table 1) . Tertiary patterns, now suggested to be referred to as minor high-grade patterns (MHGP), have also been considered in the context of GGs as recent studies have shown that MHGP can potentially add prognostic value to GG. MHGP, however, are not currently considered as an integral part of the GG and are only assessed in radical prostatectomy (RP) specimens [10] . The validation studies for GG thus far have shown the relation of GG to biochemical recurrence-free survival (BRFS) and prostate cancer-specific mortality (PCSM) in RP cohorts, using biopsy and/or RP grades [11] [12] [13] . Registrybased re-analyses have shown the strength of GG in predicting PCSM and metastasis-free survival [14] . Also recently, a radiation-treated cohort was analyzed for biopsy GG as predictor of BRFS and PCSM [15] . However, none of the studies have shown that the new GG system has increased predictive power with respect to GS, and most of the studies are hampered by short follow-up times and BRFS as the end-point for the analysis.
The weakness for BRFS as end-point is its surrogate nature [16] [17] [18] . Altogether, 30%-40% of RP-treated patients experience BRFS during post-operative follow-up [19] [20] [21] . However, presumably by the survival-prolonging effect of secondary treatments, only approximately 10% of the patients experience disease-specific mortality in 10 to 15 years after RP [22, 23] . Cohorts with an adequate number of patients and sufficient follow-up time for PCSM are rarely available. In addition, pre-magnetic resonance imaging (MRI)-era transrectal ultrasound-guided (TRUS) biopsies are prone to significant sampling error, thus higher grade prostate cancer foci are missed in up to 30% of GS 3 + 3 biopsies [24, 25] . Validation of the GG system in predicting the all-cause mortality (ACM) and PCSM compared to conventional Gleason grade pattern scores is essential in order to facilitate its use in patient communication. Here, we have validated the predictive significance of the new GG system after RP in a large patient set with substantially long follow-up time. In addition to the most important outcome, ie, survival, secondary treatment information was incorporated into the analysis. 2. Materials and methods
Patient cohort
The study cohort consisted of patients with comprehensive clinical data and accompanying RP specimens operated on between 1983 and 1998 at Helsinki University Hospital and between 2000 and 2005 at Turku University Hospital. Limited pelvic lymph node dissection accompanied most of the RPs in both cohorts. The clinical databases were combined and updated in November 2015 with the Finnish Cancer Registry's data on patients' all-cause and disease-specific mortality, resulting in a median follow-up time of 15.7 years for the Helsinki cohort (range 0.7-28.6) and 9.5 years (range 0.2-14.0) for the Turku cohort. The median post-RP follow-up time for the entire cohort for PCSM and ACM was 11.9 years, and the median age at RP was 62.4 years. For more detailed demographics of the separate Helsinki and Turku cohorts and the whole cohort, see Table 2 .
The Helsinki and Turku cohorts originally included 478 and 532 patients, respectively. For both cohorts, the original clinical RP specimen slides were re-evaluated between years 2005 and 2010 by experienced uropathologists according to the GS criteria of the ISUP 2005 consensus meeting and taking into account the commonly applied recommendations thereafter, to form the classes currently recognized as GGs (the criteria that were approved in the consensus of 2014) (Table 1) [1, 2, 26] . To avoid possible interference of accompanied treatments on tissue interpretation [1] , patients who had received neoadjuvant therapies prior to RP were excluded, leading to 401 and 503 patients in the Helsinki and Turku cohorts, respectively. Complete follow-up data were available for a total of 374 and 457 patients, who were included in the final analysis. Post-operative follow-up was conducted by clinical examinations and prostate-specific antigen (PSA) measurements at least three times during the first year after surgery and at least once a year during the following years. For the Helsinki cohort, also the complete information of the commencement dates for secondary therapies was available (Supplementary Table 1 
Statistical analysis
The primary outcomes in this study were PCSM and ACM within the first 15 years of follow-up. If outcome events occurred after 15 years, the patient's follow-up was encoded as 15 years, and censored. The secondary outcome, analyzed only in the Helsinki cohort, was initiation of secondary therapy. Kaplan-Meier survival analysis with Mantel-Haenzel log-rank test for time to PCSM, time to ACM or time to secondary therapies was performed. Additionally, univariable and multivariable Cox regression analyses were performed to assess risk for outcome events, and included age at operation, PSA at diagnosis, GG, pathological T-stage (pT), and lymph node status in the models. Competing risk analysis was performed comparing the risk of mortality by any causes and by prostate cancer, as stratified by GG. Receiver operating characteristic (ROC) area under the curve (AUC) analyses were performed for the new 5-tiered GG and 3-tiered GS (b7, 7, N7) to compare the predictive accuracy of the two grading systems. Decision curve analyses comparing net benefit of Grade Grouping versus Gleason scoring in the decisionmaking was also performed. All statistical analyses were performed using R Statistical Software v.3.3.3 (Foundation for Statistical Computing, Vienna, Austria) using the packages survival, survminer, pROC, cmprsk, and rms.
Results

Univariable survival analysis
Amongst the study population, half of the patients were originally graded as GS7 and almost one third as GS ≤ 6. After stratifying patients into GGs, GG2 and GG3 formed almost equally sized groups (Table 2 ). In Kaplan-Meier survival analyses for ACM and PCSM outcomes, remarkably, GG2 stratified patients similarly to GG1, while the survival profile of patients with GG3 was similar to those patients with GG4 or GG5 (P .0001, Fig. 2A and B) . Each unit increase in GG was significantly associated with shorter median secondary therapy treatment-free survival (P b .0001, Supplementary Fig. 1 ).
In univariable Cox proportional hazard analysis for probability of death after surgical treatment, the hazard ratio for PCSM ranged from 8.015 (P = .052, 95% CI = 0.986-65.14) to 55.799 (P b .001, 95% CI 6.717-463.52) when Fig. 2 Survival analysis of new Grade Group system and outcomes. Kaplan-Meier analyses for probability of survival during follow-up for prostate cancer-specific mortality (PCSM)-free survival (A), any cause mortality (ACM)-free survival (B). To evaluate the new Grade Grouping system with regards to significance in predicting competing outcomes, Gray's competing risk analysis (C) was performed for low (1-2) versus high (3-5) and cumulative incidence of any-cause mortality within 15 years of follow-up (ACM15) and prostate cancer-specific mortality within 15 years of follow-up (PCSM15). GG2 to GG5 were compared to reference of GG1. Similarly, increased GG was associated with increased risk of ACM and initiation of secondary therapy (Table 3) .
Multivariable survival analysis
In testing Cox proportional hazards assumption for a multivariable model with PCSM as the outcome, the lymph node status at RP was found to violate the assumption, and was assessed in a time-dependent manner of less than or equal to 6 years follow-up, or greater than 6 years follow-up. Additionally, due to the low number of PCSM events in GG1 (n = 1), our multivariable model did not converge, and thus we conducted pooled analysis of GG1 and 2 together as the reference group.
In the multivariable Cox regression analysis, pT stage and lymph node positivity predicted significant differences in PCSM. Interestingly, the increased risk of outcome events due to lymph node positivity was observed to be time dependent, with it no longer being associated with PCSM after the first 6 years of follow-up (Table 3A) .
Competing risk analysis of cause of mortality
Gray's competing risk analysis was conducted to analyze the predicted risk of patients with GG 1 and 2, versus GG 3-5 PC progressing to PCSM in comparison to patients who experienced ACM or survival. There was a significant difference of cumulative incidence by GG in patients who experienced PCSM (P b .0001) and ACM (P = .046) (Fig. 2C) .
Benefits of Grade Grouping in outcome prediction
In order to study the additive effect of GG in survival prediction, ROC-AUC analyses were performed to address the discriminatory power of three-tier GS (b7, 7, N7) and the five-tier GG with outcomes. The receiver-operating curve discriminatory analysis showed increased area under the curve (AUC) values for GG in all of the study outcomes when compared with the three-tier GS (Supplementary Fig. 2A-C) .
Lastly, decision curve analyses were performed to compare the net benefit of GG and GS in predicting outcome. Decision curve analysis plots the net benefit of predictors against all probabilities of an event occurring. This allows for comparison of different predictors in assessing the harmto-benefit ratio for clinical decision of an intervention. For all measured outcomes (PCSM, ACM and secondary therapy-free survival), across all threshold probabilities of outcome events occurring, GG performed better than, or as well as, GS (Supplementary Fig. 3 ).
Discussion
A new predictive prostate cancer grading system has recently been proposed by authors at Johns Hopkins Hospital led by the pathologist Jonathan Epstein using a fairly simple division of Gleason grade pattern sums into GG (Table 1 ) [4] . The predictive value has been validated in studies of prostate cancer patients treated with different modalities as well as in separate cohorts of RP and radiation-treated patients [12, 14, 27] . Despite studies assessing the predictive value of GG to predict hard outcomes such as PCSM [13] , few studies have comprehensively conducted rigorous discriminatory analysis of GS and GG in the same patient cohort.
Previous studies have compared GG and GS in prediction of BRFS [15, 27, 28] and have found GG to be a better predictor of outcome than GS. The strengths of these studies include large sample sizes, multi-center analyses, and diverse study populations. The studies, however, suffer from short median follow-up times, and the use of BRFS, which is considered as a surrogate endpoint. Additionally, as commented by Dell'Oglio et al, these studies did not address the most crucial unmet clinical need: assessing the possible superiority of GG over GS with regard to harder outcomes, namely PCSM [29] . In order to address these problems, two other recently published studies, have analyzed harder endpoints [30, 31] . In the study by Dell'Oglio et al, no additive benefit for GG over GS could be shown. The authors assessed performance with respect to clinical recurrence (CR), defined as detection of metastasis after BRFS, as an endpoint and a median follow-up of 5.8 years [30] . The authors speculated that a lack of plateau in their Kaplan-Meier curves might suggest increased differences between GGs with longer follow-up. The study by Grogan et al compared the predictive power of GG and GS for BRFS, CR, and PCSM in a single-center cohort. The study cohort featured a rigorous re-evaluation of GS to the ISUP 2005 standard, and a long median follow-up time of 15 years. While their study found GG to be superior to GS in predicting BRFS, CR and PCSM, the authors did not report whether GG remained an independent predictor of PCSM in multivariable analysis for PCSM, despite reporting such data for other study outcomes [31] .
To our knowledge, our study is the first multicenter study, with long-term follow-up, to demonstrate increased predictive value of GG over GS in predicting PCSM and ACM. Our study, with a median of 11.1 years follow-up, affirms the power of GG to predict long-term survival in a RP-treated cohort. Our patients had not received neoadjuvant treatments, but had been treated with adjuvant or secondary therapies at any given era according to treating urologist's discretion. Given the fact that GG remarkably associated with probability of receiving secondary therapies and stratified each group to separate survival curves, only patients in GGs 3 to 5 progressed to prostate cancer-specific death in significant numbers. It is also obvious that the greater adjuvant therapy with each successive GG likely lessened the separation of the curves in the cancerspecific mortality Kaplan-Meier curves ( Fig. 2A) since adjuvant therapy is associated with delaying the time to death.
One of the strengths of our study compared to other contemporary cohorts is the long median follow-up time needed to study survival endpoints [14] . Only by long follow-up can the significant variables independently associated with PCSM be assessed, those being age, diagnostic, pT stage, lymph node status and GG in our multivariable analysis. Regardless of the local extent of the disease, GG predicted PCSM after RP. Especially the clear depression in survival probability seen between GG2 and GG3 emphasizes the importance of volume of Gleason grade pattern 4 predominance long term for contributing to disease progression and mortality, despite secondary therapies. All of our patients have been diagnosed before 2005, and thus the treatment decisions were based on the Gleason criteria at that time. Importantly, as we aimed for long follow-up to allow survival endpoints to be studied, we chose a historical cohort, but re-evaluation of the slides was conducted according to 2005 ISUP consensus meeting, supplemented by the modifications later approved in 2014. Our study with re-evaluated RP specimens further states the use of GG in differentiation of Gleason score 7 tumors into groups with significantly different prognosis.
In addition to being a retrospective analysis, other weaknesses of our study include lack of thorough PSA data for BRFS analysis and the lack of information on the tertiary Gleason pattern in RP specimens. A recent study has evaluated how the existence of tertiary higher-grade pattern along with the new GG affects the prognosis after RP [32] . Also, as the biopsies are now more often taken under MRI-TRUS fusion guidance, the issues of undersampling can be better avoided [24] . Based on our results on RP-treated cohorts, we can postulate that GG2 patients react to adjuvant treatments better and can possibly be treated more conservatively post-operatively, or followed-up less frequently as GG ≥3 patients. Addition of tissue biomarkers, such as PTEN, to the analysis might further help stratify patients into proper follow-up or adjuvant therapies [33, 34] .
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